- Home
- DCI vs BMRN Comparison
DCI vs BMRN Comparison
Compare DCI & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCI | BMRN |
|---|---|---|
| Founded | 1915 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 10.5B |
| IPO Year | 2005 | 1999 |
Fundamental Metrics
Financial Performance| Metric | DCI | BMRN |
|---|---|---|
| Price | $88.72 | $54.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 18 |
| Target Price | ★ $99.00 | $88.22 |
| AVG Volume (30 Days) | 480.3K | ★ 1.5M |
| Earning Date | 06-02-2026 | 04-24-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.75 | ★ 1.80 |
| Revenue | ★ $2,844,900,000.00 | $1,313,646,000.00 |
| Revenue This Year | $4.58 | $15.02 |
| Revenue Next Year | $5.18 | $12.23 |
| P/E Ratio | $50.83 | ★ $30.52 |
| Revenue Growth | 4.05 | ★ 17.62 |
| 52 Week Low | $63.71 | $50.76 |
| 52 Week High | $112.84 | $66.28 |
Technical Indicators
Market Signals| Indicator | DCI | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 50.46 | 43.66 |
| Support Level | $88.50 | $51.77 |
| Resistance Level | $94.26 | $56.21 |
| Average True Range (ATR) | 1.81 | 1.36 |
| MACD | 0.66 | 0.03 |
| Stochastic Oscillator | 75.74 | 24.69 |
Price Performance
Historical ComparisonAbout DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.